Redirecting to https://www.prnewswire.com/apac/news-releases/translational-research-results-of-sacituzumab-tirumotecan-sac-tmt-in-combination-with-osimertinib-as-first-line-treatment-for-egfr-mutant-nsclc-published-in-cancer-cell-302806109.html